Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

Sangamo said it will gain development and commercialization ... Message volumes climbed to ‘extremely high’ zone from ‘low’ in the same period. Meanwhile, Barclays kept an ‘Overweight ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 billion.

Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...

Shares of Sangamo Therapeutics slumped after the company filed to terminate its deal with pharmaceutical company Pfizer. The company's stock fell 55% to $1.02 in after-hours trading Monday.

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of $2.00. Discover outperforming stocks and invest smarter ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio has given his Buy rating ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company with a market capitalization of $492 million, today announced the forthcoming reacquisition of development ...